AKT1 and Hepatic steatosis: Ceramides also substantially contribute to the augmentation of hepatic steatosis and insulin resistance in obesity by activating PKCζ and protein phosphatase 2A (PP2A), leading to impaired AKT translocation and dephosphorylation of AKT [117].